fxii (Proteintech)
Structured Review

Fxii, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fxii/product/Proteintech
Average 94 stars, based on 8 article reviews
Images
1) Product Images from "Inflammation contributes to trauma-induced coagulopathy by oxidation of multiple clotting factors"
Article Title: Inflammation contributes to trauma-induced coagulopathy by oxidation of multiple clotting factors
Journal: Redox Biology
doi: 10.1016/j.redox.2025.103956
Figure Legend Snippet: Trauma shows unique features in clotting factors in humans. The activity and protein concentration of each clotting factor, FV ( A ), FVII ( B ), FVIII ( C ), FIX ( D ), FX ( E ), FXI ( F ) and FXII ( G ) was measured using human plasma from trauma patients (n = 22) and healthy controls (n = 10) as described in Methods. Ratio of each clotting factor was calculated by dividing the activity of each factor with protein concentration. Data represent mean ± SEM. ns = not significant. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 vs. control. FV ratio, FVII concentration, FVIII activity, FIX concentration, FXI ratio and FXII ratio panels (Mann-Whitney U test), others (Student's t-test).
Techniques Used: Coagulation, Activity Assay, Protein Concentration, Clinical Proteomics, Control, Concentration Assay, MANN-WHITNEY
Figure Legend Snippet: Oxidative stress is increased and correlates with coagulopathy, inflammation, thrombin generation, and FV, FVII and FXII activities in trauma patients. A . Oxidative stress was analyzed by measuring oxidative carbonyl modification in trauma patients (n = 21, closed circle) and healthy controls (n = 10, open circle) as described in Methods. Linear regression relationship was shown between oxidative stress versus coagulopathy (PT. aPTT and fibrinogen, B ), IL6 ( C ), TGA (peak time, peak concentration, slope, lag time and AUC., D ), PGA (peak time, peak concentration, slope, lag time and AUC., E ) or the activity of each clotting factor ( F ) using Pearson correlation coefficient. Data represent mean ± SEM. ∗∗∗p < 0.001 vs. control. Mann-Whitney U test.
Techniques Used: Modification, Concentration Assay, Activity Assay, Coagulation, Control, MANN-WHITNEY
Figure Legend Snippet: FVII, FX and FXII are oxidized in trauma patients. FV ( A ), FX ( B ) and FXII ( C ) were immunoprecipitated using monoclonal antibodies against FV, FX and FXII from plasma of trauma patient (n = 5) and healthy controls (n = 4) as described in Methods. Purified FV, FX and FXII was analyzed by OxyBlot and immunoblotting using FV, FX or FXII – specific antibodies. Representative blots are displayed.
Techniques Used: Immunoprecipitation, Bioprocessing, Clinical Proteomics, Purification, Western Blot
Figure Legend Snippet: IL6-activated leukocytes mimic oxidation and reduce the activity of clotting factors shown in trauma patients while the anti-inflammatory protein, AQB-565 and antioxidant, vitamin C prevent these phenomena. IL6-stimulated RBC-lysed leukocytes from healthy donors (n = 5) were incubated with FVII, FX and FXII, or AQB-565 and vitamin C as described in Methods for 4 h. After that, FVII, FX and FXII were isolated by immunoprecipitation as described in Methods. Purified FV ( A ), FX ( B ) and FXII ( C ) was analyzed by OxyBlot and immunoblotting using FV, FX or FXII – specific antibodies (left panel). Representative blots are displayed. Also, each activity of these coagulation factors was measured in isolated FVII, FX and FXII as described in methods (right panel). Data represent mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 vs. IL6. ANOVA and Tukey post-hoc test.
Techniques Used: Activity Assay, Coagulation, Incubation, Isolation, Immunoprecipitation, Purification, Western Blot
Figure Legend Snippet: Each clotting factor shows distinct and unique roles in thrombin generation and ROTEM. TGA ( A , C , E , G , and I ) and ROTEM ( B , D , F , H , J ) were performed using each clotting factor-specific DP (n = 3) as described in Methods. A and B . control amount (control) of FV which we found in healthy controls or reduced amount (treated) of FV which we found in trauma patients were added in FV DP. Variables from TGA, lag time, peak time, slope, peak concentration and AUC, or variables from ROTEM, clotting time, a-angle, maximum clot firmness were obtained in each experiment as described in Methods. C and D . control FVII (control) and oxidized FVII (treated) which were obtained by incubation with leukocytes as described in Methods were added to FVII DP. E and F . control amount (control) or excess amount (treated)of FVIII were added to FVIII DP. G and H . control FX (control) and oxidized FX (treated) which were obtained by incubation with leukocytes as described in Methods were added to FX DP. I and J . control FXII (control) and oxidized FXII (treated) which were obtained by incubation with leukocytes as described in Methods were added to FXII DP. Data represent mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 vs. control. Student's t-test.
Techniques Used: Coagulation, Control, Concentration Assay, Incubation